Taiwan Liposome PhI/II trial on acupuncture-type arthritis candidate fully enrolled

Taiwan map

Taiwan Liposome has achieved full enrollment for its 12-week Phase I/II candidate to treat arthritis, TLC599, a therapy administered akin to acupuncture through a microneedle that enables it to penetrate small joints.

The corticosteroid therapy is encapsulated in a lipid and injected using the company’s BioSeizer platform. Trial results--aimed at showing a marked difference between current steroid osteoarthritis treatments on frequency and the length of pain relief efficacy--are expected by the second half of 2016.

Taiwan Liposome said current steroid treatments are limited to a few each year to mitigate side effects, while efficacy is limited to around two weeks.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

Taiwan Liposome said in an announcement that it expected a sustained release action will provide longer relief from arthritis stiffness and pain, with 29 of the 40 patients enrolled in the study already having completed a 12-week observation period. Interim efficacy results appear "favorable."

Taiwan's biotech sector was rocked earlier this year by the resignation of Wong Chi-Huey as president of Academia Sinica, which related to the timing of a share sale in OBI Pharma by his daughter.

But investors remain upbeat on the sector in Taiwan with the potential for firms like Taiwan Liposome to get products more easily into heavyweight China.

- here's the release

Related Articles:
James Liao named as new candidate to helm Taiwan's Academia Sinica
Taiwan's outgoing leader touts biotech growth


Suggested Articles

Several Johnson & Johnson drugs are contributing strong growth, but some struggling medicines weighed on the company's overall performance.

J&J has received its fair share of barbs Oklahoma's bench trial. Whether it'll be held responsible for the state's opioid crisis is now up…

J&J's pharma unit is still on the upswing, thanks to newer meds like Stelara, but execs had to explain disappointing numbers from two blockbusters.